1. bookVolume 22 (2014): Issue 3 (September 2014)
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

Genotype-phenotype correlations in patients treated with acenocoumarol / Corelaţii genotip-fenotip la pacienţii trataţi cu acenocumarol

Published Online: 08 Oct 2014
Page range: 347 - 354
Received: 13 May 2014
Accepted: 10 Aug 2014
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Abstract

Aim: This research aims to establish a genotype-phenotype correlation in patients treated with acenocoumarol and studies the genetic factors (VKORC1 and CYP2C9 polymorphisms) that may influence INR values during initiation of oral anticoagulant therapy with acenocoumarol. Material and methods: We included 131 patients that needed treatment with acenocoumarol, 70 (53.4%) women and 61 (46.6%) men, observed at the 5th Medical Clinic in Cluj-Napoca, between 2009-2011. We studied the influence of age, gender, concomitant medication and of CYP2C9 and VKORC1 genes on the INR value recorded on the third day of treatment and on the difference between this value and the initial INR value at the starting point for the treatment (INRDIF). Results and conclusion: We demonstrated a statistically significant difference for INR3 and INRDIF values in patients with AA genotype and those with GG genotype of the c.-1639G>A polymorphism of the VKORC1 gene. The presence of AA genotype of the c.-1639G>A polymorphism of the VKORC1 gene determined a 15.7-fold increase in the risk that a patient might display supratherapeutic INR after 2 days of treatment with 4 mg of acenocoumarol

Keywords

Cuvinte cheie

1. Wolkanin-Bartnik J, Pogorzelska H, Szperl M, Bartnik A, Koziarek J, Bilinska ZT. Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm. Pharmacogenet Genomics. 2013;23(11):611-8. DOI: 10.1097/ FPC.000000000000000410.1097/FPC.0000000000000004Search in Google Scholar

2. Daly AK. Pharmacogenomics of anticoagulants: steps toward personal dosage. Genome Med. 2009;1(1):10. DOI: 10.1186/gm1010.1186/gm10Search in Google Scholar

3. Buzoianu AD, Trifa AP, Mureşanu DF, Crişan S. Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe. J Cell Mol Med. 2012;16(12):2919-24. DOI: 10.1111/j.1582-4934.2012.01606.x10.1111/j.1582-4934.2012.01606.xSearch in Google Scholar

4. Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos. 2000;28(11):1284-90.Search in Google Scholar

5. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005;106(1):135-40. DOI: 10.1182/blood-2005-01-034110.1182/blood-2005-01-0341Search in Google Scholar

6. Pop TR, Vesa Ş, Trifa AP, Crişan S, Buzoianu AD. An acenocoumarol dose algorithm based on a South-Eastern European population. Eur J Clin Pharmacol. 2013;69(11):1901-7. DOI: 10.1007/s00228-013-1551-310.1007/s00228-013-1551-3Search in Google Scholar

7. Anton AI, Cerezo-Manchado JJ, Padilla J, Perez-Andreu V, Corral J, Vicente V, et al. Novel associations of VKORC1 variants with higher acenocoumarol requirements. PLoS One. 2013;8(5):e64469. DOI: 10.1371/ journal.pone.006446910.1371/journal.pone.0064469Search in Google Scholar

8. Verhoef TI, Redekop WK, Buikema MM, Schalekamp T, Van Der Meer FJ, Le Cessie S, et al; EU-PACT Group. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. J Thromb Haemost. 2012;10(4):606-14. DOI: 10.1111/j.1538-7836.2012.04633.x10.1111/j.1538-7836.2012.04633.xSearch in Google Scholar

9. Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P4502C9 polymorphisms. Clin Pharmacol Ther. 2005;77(1):1-16. DOI: 10.1016/j. clpt.2004.08.009Search in Google Scholar

10. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, et al. VKORC1 haplotypes and their impact on the inter individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost. 2005;94(4):773-9.Search in Google Scholar

11. Montes R, de Gaona RE, Martinez-Gonzalez MA, Alberca I, Hermida J. The c._1639G4A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol. 2006;133(2):183-187. DOI: 10.1111/j.1365-2141.2006.06007.x10.1111/j.1365-2141.2006.06007.xSearch in Google Scholar

12. Wen MS, Lee M, Chen JJ, Chuang HP, Lu LS, Chen CH, et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther. 2008;84(1):83-9. DOI: 10.1038/ sj.clpt.610045310.1038/sj.clpt.6100453Search in Google Scholar

13. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006;129(5):1155-66. DOI: 10.1378/chest.129.5.115510.1378/chest.129.5.1155Search in Google Scholar

14. Spreafico M, Lodigiani C, van Leeuwen Y, Pizzotti D, Rota LL, Rosendaal F, et al. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics. 2008;9(9):1237-50. DOI: 10.2217/14622416.9.9.123710.2217/14622416.9.9.1237Search in Google Scholar

15. Teichert M, van Schaik RH, Hofman A, Uitterlinden AG, de Smet PA, Stricker BH, et al. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther. 2009;85(4):379-86. DOI: 10.1038/clpt.2008.29410.1038/clpt.2008.294Search in Google Scholar

16. Schalekamp T, Brassé BP, Roijers JFM, Chahid Y, van Geest-Daalderop JH, de Vries-Goldschmeding H, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther. 2006;80(1):13-22. DOI: 10.1016/j.clpt.2006.04.00610.1016/j.clpt.2006.04.006Search in Google Scholar

17. Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM. Influence of CYP2C9 and VKORC1 on Warfarin Response during Initiation of Therapy. Blood Cells Mol Dis. 2009;43(1):119-128. DOI: 10.1016/j. bcmd.2009.01.019Search in Google Scholar

18. Pérez-Andreu V1, Roldán V, Antón AI, García-Barberá N, Corral J, Vicente V, et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood. 2009;113(20):4977-9. DOI: 10.1182/ blood-2008-09-176222 10.1182/blood-2008-09-176222Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo